Defects in the homologous recombination (HR) repair pathway are of clinical interest due to sensitivity of HR-deficient cells to PARP inhibitors. We were interested in defining PARP vulnerability in patients with metastatic colorectal cancer (mCRC) carrying KRAS and BRAF mutations who display poor prognosis, have limited therapeutic options, and represent an unmet clinical need.
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Arena, SabrinaFirst
;Corti, Giorgio;Russo, Mariangela;Lorenzato, Annalisa;Arcella, Pamela;Rospo, Giuseppe;Pagani, Massimiliano;Negrino, Carola;Isella, Claudio;Mittica, Gloria;Medico, Enzo;Di Nicolantonio, Federica;Bardelli, AlbertoLast
2019-01-01
Abstract
Defects in the homologous recombination (HR) repair pathway are of clinical interest due to sensitivity of HR-deficient cells to PARP inhibitors. We were interested in defining PARP vulnerability in patients with metastatic colorectal cancer (mCRC) carrying KRAS and BRAF mutations who display poor prognosis, have limited therapeutic options, and represent an unmet clinical need.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1078-0432.CCR-19-2409.full.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
1.04 MB
Formato
Adobe PDF
|
1.04 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
1078-0432.CCR-19-2409.full.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
11.58 MB
Formato
Adobe PDF
|
11.58 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
